In other recent news, MannKind Corporation announced its acquisition of scPharmaceuticals Inc. in a deal valued at up to $360 million. The agreement includes an upfront payment of $5.35 per share in cash, with an additional non-tradable contingent value right worth up to $1.00 per share, contingent on achieving certain regulatory and sales milestones. This acquisition marks MannKind's expansion into cardiorenal medicine. In related developments, scPharmaceuticals reported its Q2 2025 earnings, with net revenue reaching $16 million, a 99% increase year-over-year, surpassing forecasts. However, the earnings per share fell short of expectations at -$0.34, compared to the anticipated -$0.29. Additionally, scPharmaceuticals has amended its supply agreement with West Pharmaceutical Services, extending the arrangement through December 31, 2027. The amendment outlines specific terms for termination and payment responsibilities.